Drugs / ENB003
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04205227 | Feb 2020 → Jan 2026 overdue | malignant pancreatic neoplasm, melanoma, ovarian cancer | ENB Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04918186 | May 2022 → Dec 2026 expected | ovarian cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENB003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04918186 ↗ |
| Action | Inhibit | “ENB003 is selective Endothelin B Receptor Antagonist” NCT04205227 ↗ |